(Q24243067)

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Amiodarone versus sotalol for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

A comparison of rate control and rhythm control in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Dep

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Clinical efficacy of flecainide acetate in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Sustained-release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroversion of atrial dysrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Dofetilide: a review of its use in atrial fibrillation and atrial flutter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Appropriate outcome measures in trials evaluating treatment of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Pharmacological cardioversion for atrial fibrillation and flutter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Circumferential pulmonary-vein ablation for chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Incidence of chronic atrial fibrillation in general practice and its treatment pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

Amiodarone in the management of refractory atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

[Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Efficacy of amiodarone for refractory supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Amiodarone for refractory atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Propafenone for paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Propafenone for prevention of recurrent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Usefulness of propafenone for recurrent paroxysmal atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Therapeutic efficacy and safety of oral propafenone for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

1 reference

7 January 2021

Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

[Propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

[Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Amiodarone in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Double-Blind Evaluation of Practolol and Quinidine in the Treatment of Chronic Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Side effects of long-term amiodarone therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021

Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005049.PUB2

7 January 2021